Evidence map›Paper›PMID 34382380›Full record

SynthesisNeuropsychopharmacology reports2021

Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review.

Hayahito Ishikawa, Masahiro Takeshima, Hiroyasu Ishikawa, Naoko Ayabe, Hidenobu Ohta, Kazuo Mishima

Open access · goldAbstract readCase ReportsSystematic Review
In one paragraph

Synthesis in Neuropsychopharmacology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Pregabalin dependence - A rising concern.Industrial psychiatry journal · 2024
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hayahito IshikawaDepartment of Neuropsychiatry, Japanese Red Cross Akita Hospital, Akita City, Japan.
Masahiro TakeshimaDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita City, Japan.ORCID 0000-0003-0614-7524
Hiroyasu IshikawaDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita City, Japan.
Naoko AyabeDepartment of Regional Studies and Humanities, Faculty of Education and Human Studies, Akita University, Akita City, Japan.
Hidenobu OhtaDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita City, Japan.
Kazuo MishimaDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita City, Japan.ORCID 0000-0003-1182-1181
Akita University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pregabalin is a drug that can cause psychiatric symptoms via pregabalin withdrawal. Prior reports on pregabalin withdrawal have mainly focused on cases with pregabalin dependence or abuse, and little attention has been paid to patients who are prescribed regular doses of pregabalin. Herein, we report three cases of pregabalin withdrawal in patients without psychiatric disorders, taking regular doses of pregabalin, who developed psychiatric symptoms such as insomnia and anxiety after abrupt discontinuation of pregabalin. In addition, we conducted a systematic review of six case reports (previous studies) of pregabalin withdrawal under regular doses of pregabalin. Among the six cases, three patients had no comorbid mental or substance use disorders, the dose of pregabalin ranged from 150 to 600 mg/d, and the duration of pregabalin use ranged from a few weeks to many years. Of these six cases of pregabalin withdrawal, five had psychopathological symptoms, three had vegetative symptoms, and three had neurologic and physical complications. We concluded that since pregabalin withdrawal can occur even with regular doses and short-term use, clinicians must carefully reduce pregabalin doses when reducing or discontinuing treatment, paying close attention to withdrawal symptoms. Our case series sheds light on the scant evidence from previous research on physical dependence in patients who are taking regular doses of pregabalin. Furthermore, our cases were also valuable in demonstrating that pregabalin withdrawal can occur even after a relatively short period of 2 months.

Indexed as

Substance-Related DisordersSubstance Withdrawal SyndromeAnxietyAnxiety DisordersHumansPregabalinPregabalinanxietydependenceinsomniapregabalinwithdrawal

Identifiers

PMID34382380
PMCPMC8411313
OpenAlexW3192781804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.